for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Applied Therapeutics Inc

APLT.OQ

Latest Trade

19.10USD

Change

-0.22(-1.14%)

Volume

11,947

Today's Range

18.52

 - 

19.67

52 Week Range

13.59

 - 

33.34

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
19.32
Open
19.38
Volume
11,947
3M AVG Volume
1.97
Today's High
19.67
Today's Low
18.52
52 Week High
33.34
52 Week Low
13.59
Shares Out (MIL)
26.08
Market Cap (MIL)
498.16
Forward P/E
-3.94
Dividend (Yield %)
--

Next Event

Q2 2021 Applied Therapeutics Inc Earnings Release

Latest Developments

More

Applied Therapeutics Granted Fast Track Designation By FDA For AT-007 For Galactosemia

Applied Therapeutics Reports Q1 Loss Per Share Of $1.00

Applied Therapeutics Says On Track To Submit NDA For AT-007 in Galactosemia

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Applied Therapeutics Inc

Applied Therapeutic, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of product candidates against validated molecular targets in indications of unmet medical need. Its molecular target is aldose reductase (AR), which is an enzyme and rate-limiting step in the polyol pathway, an alternative glucose metabolism pathway. Its lead product candidate, AT-001, is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. Its other product candidates include AT-007, AT-003 and AT-104. AT-001, is an aldose reductase inhibitor (ARI) with exposure and nerve permeability. AT-001 is developed for the treatment of diabetic cardiomyopathy (DbCM), a fatal fibrosis of the heart. Its AT-007 is a central nervous system (CNS) penetrant ARI, which is developed for the treatment of galactosemia. Its AT-003 is an ARI designed to cross through the back of the eye when dosed orally. AT-003 is developed for the treatment of diabetic retinopathy (DR).

Industry

Biotechnology & Drugs

Contact Info

545 5TH AVENUE, SUITE 1400

NEW YORK, NY

10017

United States

+1.212.2209319

http://www.appliedtherapeutics.com/

Executive Leadership

Shoshana Shendelman

Chairman of the Board, President, Chief Executive Officer, Founder

Charles Silberstein

Chief Financial Officer

Adam Hansard

Chief Commercial Officer

Riccardo Perfetti

Chief Medical Officer

Teena L. Lerner

Lead Independent Director

Key Stats

1.86 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2019

-3.550

2020

-4.280

2021(E)

-4.844
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
3.67
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-71.99
Return on Equity (TTM)
-65.68

Latest News

Latest News

BRIEF-Applied Therapeutics Announces Start Of At-007 Pediatric Galactosemia Study

* APPLIED THERAPEUTICS ANNOUNCES START OF AT-007 PEDIATRIC GALACTOSEMIA STUDY; RELEASES ADDITIONAL 40MG/KG DATA FROM ADULT GALACTOSEMIA STUDY

BRIEF-Applied Therapeutics Files For Mixed Shelf Of Upto $300 Mln

* APPLIED THERAPEUTICS, INC FILES FOR MIXED SHELF OF UPTO $300 MILLION - SEC FILING Source text: (https://bit.ly/2ABQq2l) Further company coverage:

BRIEF-Applied Therapeutics Announces Appointment Of Chuck Silberstein As Chief Financial Officer And Head Of Business Development

* APPLIED THERAPEUTICS ANNOUNCES APPOINTMENT OF DR. CHUCK SILBERSTEIN, MD, MBA, CFA AS CHIEF FINANCIAL OFFICER AND HEAD OF BUSINESS DEVELOPMENT

BRIEF-Applied Therapeutics Files Prospectus Supplement Related To Offering Of 1.4 Mln Shares Of Common Stock By Selling Stockholders

* APPLIED THERAPEUTICS INC FILES PROSPECTUS SUPPLEMENT RELATED TO OFFERING OF 1.4 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS Source: https://bit.ly/2WjlpbM Further company coverage:

BRIEF-Applied Therapeutics Reports First Quarter 2020 Financial Results

* APPLIED THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS

BRIEF-Applied Therapeutics Says As Of Now, Co Has Not Experienced Any Significant Delays To Ongoing Or Planned Clinical Trials

* APPLIED THERAPEUTICS - AS OF NOW, CO HAS NOT EXPERIENCED ANY SIGNIFICANT DELAYS TO ITS ONGOING OR PLANNED CLINICAL TRIALS Source: https://bit.ly/2Kjaus1 Further company coverage:

BRIEF-Applied Therapeutics Announces Full Data And Scientific Presentations From The Pivotal Phase 2 Action-Galactosemia Trial

* APPLIED THERAPEUTICS ANNOUNCES FULL DATA AND SCIENTIFIC PRESENTATIONS FROM THE PIVOTAL PHASE 2 ACTION-GALACTOSEMIA TRIAL

BRIEF-Applied Therapeutics Says Hospitals In New York City Have Commenced Investigator-Initiated Studies

* APPLIED THERAPEUTICS ANNOUNCES IND AND INVESTIGATOR-INITIATED STUDIES OF AT-001 IN CRITICAL COVID-19 PATIENTS

IFR US ECM WEEKLY WRAP-UP

WEEKLY TOTAL $4.58bn – IPO $800m – ABB/BLOCK $782m – FOLLOW-ON $2.45bn – CB $550m TUESDAY

IFR US ECM Calendar

Adaptive Biotechnologies (US, biotech) – $212.0m FO. 8m shares (100% sec) at $26.50 versus $26.85 last sale and $26.80 launch. JPM, GS, BOFA.

IFR US ECM Calendar

Adaptive Biotechnologies (US, biotech) – $212.0m FO. 8m shares (100% sec) at $26.50 versus $26.85 last sale and $26.80 launch. JPM, GS, BOFA.

IFR US ECM Calendar

Ares Commercial Real Estate (US, mortgage REIT) – $64.4m Block. 4m shares (100% prim) at $16.09 versus $16.09-$16.38 marketing and $16.54 last sale. WF, CITI, MS.

UPDATE 1-IFR US ECM Calendar

Adaptimmune Therapeutics (UK, biotech) – $84m ABB. 21m shares at (100% prim) $4.00 versus $4.14 last sale. COWN. Upsized from $75m.

IFR US ECM Calendar

Adaptimmune Therapeutics (UK, biotech) – $84m ABB. 21m shares at (100% prim) $4.00 versus $4.14 last sale. COWN. Upsized from $75m.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up